Evidence-based policies for new medicines

Electronic versions

Impact Summary for the General Public

Research at Bangor University’s Centre for Health Economics and Medicines Evaluation has had significant influence on pharmaceutical policy development across the UK. This has impacted directly on the parameters by which the prices of new medicines are to be set in the UK, and how the All Wales Medicines Strategy Group (AWMSG) and the National Institute for Health and Care Excellence (NICE) appraise treatments for rare diseases. Research findings have also defined the methods by which biosimilar medicines are appraised in Wales, and underpinned the Welsh (2012) and Scottish (2013) Governments' decisions against establishing Cancer Drugs Funds.

Category of impact

  • Policy and Public Services

Research outputs (4)

View all

Projects (1)

View all